1. Home
  2. FIGR vs CYTK Comparison

FIGR vs CYTK Comparison

Compare FIGR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FIGR

Figure Technology Solutions Inc.

N/A

Current Price

$72.64

Market Cap

8.3B

Sector

Finance

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$63.22

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIGR
CYTK
Founded
2018
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
8.0B
IPO Year
2025
2004

Fundamental Metrics

Financial Performance
Metric
FIGR
CYTK
Price
$72.64
$63.22
Analyst Decision
Buy
Strong Buy
Analyst Count
9
16
Target Price
$56.89
$82.38
AVG Volume (30 Days)
3.8M
2.2M
Earning Date
11-19-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$382,600,000.00
$87,211,000.00
Revenue This Year
$74.99
$339.72
Revenue Next Year
$34.64
$79.08
P/E Ratio
$279.72
N/A
Revenue Growth
137.06
2609.26
52 Week Low
$30.01
$29.31
52 Week High
$76.57
$70.98

Technical Indicators

Market Signals
Indicator
FIGR
CYTK
Relative Strength Index (RSI) N/A 50.00
Support Level N/A $60.30
Resistance Level N/A $65.35
Average True Range (ATR) 0.00 3.01
MACD 0.00 -0.01
Stochastic Oscillator 0.00 57.11

Price Performance

Historical Comparison
FIGR
CYTK

About FIGR Figure Technology Solutions Inc.

Figure Technology Solutions Inc is a suite of blockchain-based products and solutions centered around the vision of promoting efficiency and liquidity in financial markets. The company offers a technology-enabled loan origination system and paired this system with a distribution marketplace, Figure Connect, providing access to a deep and broad pool of capital markets partners.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: